Pharma firms turn attention to hearing loss

Hearing loss affects 36 million Americans to some degree, often leaving them feeling isolated, but it has received little attention from the pharmaceutical industry—until now. Small firms have brought a handful of potential therapies to the development pipeline, and pharmaceutical heavyweights are taking notice, according to an article in Chemical & Engineering News (C&EN), the weekly magazine of the American Chemical Society.

The story states that the most common cause of hearing loss is loud noise, either from a single event like the bang of a firecracker or from chronic exposure, say daily listening to a cranked-up iPod. Although severe hearing loss can be treated with a hearing aid or cochlear implants, options are scarce for those suffering from milder damage. But there is growing interest to fill the void and to even develop preventative treatments. Several drug candidates have already advanced through early clinical testing in patients.

Lisa M. Jarvis, a senior editor at C&EN, notes that potential treatments generally focus on two areas: the inner ear, where sound is first perceived, and the central nervous system (including the brain), where sound is processed. Researchers are using small molecules and gene therapy approaches to target different components, from re-growing the ear's hair cells to controlling how nerve cells involved in hearing work. Small companies firing up the field such as Audion Therapeutics have shown enough success that deeper-pocketed firms Eli Lilly & Co., Novartis and Roche are backing them up.

More information: "Sound Science" cen.acs.org/articles/92/i14/Sound-Science.html

Related Stories

Implanted hearing device approved

date Mar 20, 2014

(HealthDay)—The first implantable device for adults with a severe or profound form of a condition called "sensorineural hearing loss" has been approved by the U.S. Food and Drug Administration.

Imbalanced hearing is more than a mild disability

date Mar 12, 2014

Researchers at Washington University School of Medicine in St. Louis have received a five-year, $3 million grant from the National Institutes of Health (NIH) to study the effects of asymmetric hearing loss ...

Recommended for you

US aims to cut antibiotic use

date 7 hours ago

US President Barack Obama on Friday rolled out plans to cut inappropriate antibiotic use by half, in an effort to tackle drug resistance.

Questions over value of new antibiotics to tackle resistance

date Mar 26, 2015

In the first installment of a new series, Peter Doshi, Assistant Professor at the University of Maryland School of Pharmacy and Associate Editor at The BMJ, asks why authorities are approving drugs with little evidence they d ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.